Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
about
The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancerPCAF acetylates {beta}-catenin and improves its stabilityCrystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitmentColorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approachesSuppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARαTargeting peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification.Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cellsAssociation of Wnt1/beta-catenin with clinical pathological characteristics and prognosis of esophageal squamous cell carcinomaNovel targets for prostate cancer chemoprevention.Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomasAV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model.Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cellsIntervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasisHuaier aqueous extract inhibits ovarian cancer cell motility via the AKT/GSK3β/β-catenin pathway.sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer.MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signalingDownregulation of miR-200a induces EMT phenotypes and CSC-like signatures through targeting the β-catenin pathway in hepatic oval cells.Integrin regulation of beta-catenin signaling in ovarian carcinoma.CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.Overexpression of FRAT1 is associated with malignant phenotype and poor prognosis in human gliomas.Induction of cancer cell death by isoflavone: the role of multiple signaling pathways.Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus.Analysis of Wnt signalling dynamics during colon crypt development in 3D culture.Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase InhibitorsA MicroRNA Screen Identifies the Wnt Signaling Pathway as a Regulator of the Interferon Response during Flavivirus Infection.Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform.The canonical Wnt signalling pathway and its APC partner in colon cancer development.Targeting the Wnt signaling pathway to treat Barrett's esophagus.The protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs.Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferationNovel strategies targeting cancer stem cells through phytochemicals and their analogsDirect Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse OriginUpregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell linesCellular signaling perturbation by natural products.In vitro models of pancreatic cancer for translational oncology research.Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures.Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.Lysine 394 is a novel Rad6B-induced ubiquitination site on beta-catenin.
P2860
Q24613730-705D6565-6DB7-4825-8CAC-2A8FA991316DQ24654901-8EAE714A-5B32-4D0D-87A4-5B0DCD0CB40EQ27677080-0A576294-301B-4B0C-AED9-D127DA181B18Q28222785-F741C4E7-2C83-45A4-BF71-E5818FE37FEEQ28298718-69DEBB71-2B8D-40C2-93C7-BBDB2FFA0A9EQ28479206-AE90FC03-A98B-4C88-BD70-33B1B5DC9E7EQ33723801-77625AD4-8F3D-404A-AAAC-999FCB037234Q33772604-867ADC54-E3F7-45D5-88E4-0B703CD167BBQ34112144-7EAEB6B2-CD23-417E-B334-5EE50D64E0D8Q34289576-D1F2C386-5971-4866-AFA8-4EACB91B8947Q34346138-44F3FD66-16A9-4574-8ECC-AB72E8FE3EE9Q34350571-30FD4FDA-8F4D-4DF6-B286-FCB9701ACA91Q34429613-8A3C0177-0985-4346-B3D6-F4D9A733FCEEQ34551546-B61149B3-97DD-403F-AB58-F142D976411AQ34718388-82AD1908-0938-4DEE-8B78-73B4887310FCQ34904445-9CBEDE4B-B6D9-416D-B1E2-E0F183836B96Q34988570-50DD3666-67B2-4F6C-A7BE-0ACA3E440D85Q34991249-AADDC60C-5217-447A-992C-5451C97AD3ECQ35048411-20427CB4-EC43-4C3D-84C3-B5809AF452A7Q35067867-B63A27CC-9C8D-4780-ABF2-8160E9720576Q35116847-6F5D3BF9-7216-4C07-B684-5558C74E44E1Q35438184-1CE8CBA9-33F9-4989-A912-448E81D31D5AQ35628160-55305012-B73C-4EA1-A321-A335B901BAE8Q35631729-A6742B32-89EF-4C47-B926-996212842FFFQ35754534-128CE045-C33A-4D8B-B4BB-2C171522C8A0Q36059801-6BDEDC85-35C5-4F2B-973B-CCA0A32FED7AQ36266860-F9AB716F-BC35-44F4-A2D9-2D1A775D61FDQ36412671-F776A212-5C6C-4211-83FE-6F81DCC157BCQ36535617-745780CF-6309-435C-A3E4-71E43B193F53Q36734947-C2DFEE02-7B99-4EA5-B539-1E412192AA6FQ36947861-B7C3C461-1AEF-468A-8FD0-3C918E1FDA6DQ37086749-A2AC2081-31DC-4389-A31F-3937883B6B55Q37198168-AD7FD846-9375-4791-B5AC-A1676A9A71DCQ37231321-6A81EFDA-10EA-49FE-9FA6-24C5EAA04D06Q37243444-8C794F14-9735-48E7-BF49-E2ED442C0577Q37373545-696C76EB-092A-4650-A201-B8B466CB5CA6Q37384842-D7F803BA-ADC4-4547-9BDC-EEA464D4E7BCQ37431637-91DF23B8-DF35-4F73-A5E5-D8BD75451613Q37536500-451B3A7C-E18C-43BF-95CD-7B16939D18EEQ37559863-E2692DF3-4DB2-410F-B23F-DE1CD4A34F12
P2860
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
@ast
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
@en
type
label
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
@ast
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
@en
prefLabel
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
@ast
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
@en
P2860
P356
P1476
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.
@en
P2093
Magnus von Knebel Doeberitz
Susanne Dihlmann
P2860
P304
P356
10.1002/IJC.20609
P577
2005-02-01T00:00:00Z